Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle

Diabetes

Volumn 56, Issue 6, 2007, Pages 1630-1637

  Glund, Stephan ^a   Deshmukh, Atul ^a   Yun, Chau Long ^a   Moller, Theodore ^a   Koistinen, Heikki A ^b   Caidahl, Kenneth ^a   Zierath, Juleen R ^a   Krook, Anna ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN S6; STAT3 PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE TRANSPORT; HUMAN; INCUBATION TIME; MALE; NORMAL HUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; VASTUS LATERALIS MUSCLE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADULT; BIOLOGICAL TRANSPORT; BIOPSY; GLUCOSE; GLYCOGEN; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; REFERENCE VALUES; SIGNAL TRANSDUCTION;

EID: 34249682779     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/db06-1733     Document Type: Article

References (51)

1. Lazar MA: How obesity causes diabetes: not a tall tale. Science 307:373-375, 2005
2. Hotamisligil GS: Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 27:S53-S55, 2003
3. Tomas E, Kelly M, Xiang X, Tsao TS, Keller C, Keller P, Luo Z, Lodish H, Saha AK, Unger R, Ruderman NB: Metabolic and hormonal interactions between muscle and adipose tissue. Proc Nutr Soc 2:381-385, 2004
4. Pedersen BK, Febbraio MA, Mooney RA: Interleukin-6 does/does not have a beneficial role in insulin sensitivity and glucose homeostasis. J Appl Physiol 102:814-819, 2007
5. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 280:E745-E751, 2001
6. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW: Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab 82:4196-4200, 1997
7. Bastard JP, Maachi M, van Nhieu JT, Jardel C, Bruckert E, Grimaldi A, Robert JJ, Capeau J, Hainque B: Adipose tissue IL-6 content correlates with resistance to insulin activation of glucose uptake both in vivo and in vitro. J Clin Endocrinol Metab 87:2084-2089, 2002
8. Heliovaara MK, Teppo AM, Karonen SL, Tuominen JA, Ebeling P: Plasma IL-6 concentration is inversely related to insulin sensitivity, and acute-phase proteins associate with glucose and lipid metabolism in healthy subjects. Diabetes Obes Metab 7:729-736, 2005
9. Carey AL, Bruce CR, Sacchetti M, Anderson MJ, Olsen DB, Saltin B, Hawley JA, Febbraio MA: Interleukin-6 and tumor necrosis factor-a are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029-1037, 2004
10. Febbraio MA, Pedersen BK: Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev 33:114-119, 2005
11. Ostrowski K, Rohde T, Zacho M, Asp S, Pedersen BK: Evidence that interleukin-6 is produced in human skeletal muscle during prolonged running. J Physiol (Lond) 508:949-953, 1998
12. Pedersen BK, Febbraio M: Muscle-derived interleukin-6: a possible link between skeletal muscle, adipose tissue, liver, and brain Brain Behav Immun 19:371-376, 2005
13. Febbraio MA, Pedersen BK: Muscle-derived interleukin-6: mechanisms for activation and possible biological roles. FASEB J 16:1335-1347, 2002
14. Febbraio MA, Steensberg A, Starkie RL, McConell GK, Kingwell BA: Skeletal muscle interleukin-6 and tumor necrosis factor-alpha release in healthy subjects and patients with type 2 diabetes at rest and during exercise. Metabolism 52:939-944, 2003
15. Senn JJ, Klover PJ, Nowak IA, Zimmers TA, Koniaris LG, Furlanetto RW, Mooney RA: Suppressor of cytokine signaling-3 (SOCS-3), a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes. J Bio Chem 278:13740-13746, 2003
16. Senn JJ, Klover PJ, Nowak IA, Mooney RA: Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391-3399, 2002
17. Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45784, 2003
18. Rotter Sopasakis V, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz M, Yang X, Jansson PA, Smith U: High local concentrations and effects on differentiation implicate interleukin-6 as a paracrine regulator. Obes Res 12:454-460, 2004
19. Carey AL, Steinberg GR, Macaulay SL, Thomas WG, Holmes AG, Ramm G, Prelovsek O, Hohnen-Behrens C, Watt MJ, James DE, Kemp BE, Pedersen BK, Febbraio MA: IL-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688-2697, 2006
20. Al-Khalili L, Bouzakri K, Glund S, Lönnqvist F, Koistinen HA, Krook A: Signalling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 12:3364-3375, 2006
21. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, Noh HL, Cho YR, Cline G, Kim YB, Kim JK: Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060-1067, 2004
22. Rotter Sopasakis V, Larsson BM, Johansson A, Holmäng A, Smith U: Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47:1879-1887, 2004
23. Wallenius V, Wallenius K, Ahrén B, Rudling M, Carlsten H, Dickson SL, Ohlsson C, Jansson JO: Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75-79, 2002
24. Zierath JR: In vitro studies of human skeletal muscle: hormonal and metabolic regulation of glucose transport. Acta Physiol Scand 155:1-96, 1995
25. Young DA, Ho RS, Bell PA, Cohen DK, McIntosh RH, Nadelson J, Foley JE: Inhibition of hepatic glucose production by SDZ 51641. Diabetes 11:1408-1413, 1990
26. Cuendet GS, Loten EG, Jeanrenaud B, Renold AE: Decreased basal, noninsulin-stimulated glucose uptake and metabolism by skeletal soleus muscle isolated from obese-hyperglycemic (ob/ob) mice. J Clin Invest 58:1078-1088, 1976
27. Krook A, Moller DE, Dib K, O'Rahilly S: Two naturally occurring mutant insulin receptors phosphorylate insulin receptor substrate-1 (IRS-1) but fail to mediate the biological effects of insulin. J Biol Chem 271:7134-7140, 1996
28. Fernandez-Real JM, Broch M, Vendrell J, Gutierrez C, Casamitjana R, Pugeat M, Richart C, Ricart W: Interleukin-6 gene polymorphism and insulin sensitivity. Diabetes 49:517-520, 2000
29. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, Woo P: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102:1369-1376, 1998
30. Weigert C, Hennige AM, Brodbeck K, Haring HU, Schleicher ED: Interleukin-6 acts as insulin sensitizer on glycogen synthesis in human skeletal muscle cells by phosphorylation of Ser473 of Akt. Am J Physiol Endocrinol Metab 289:E251-E257, 2005
31. Kamimura D, Ishihara K, Hirano T: IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149:1-38, 2003
32. Klover PJ, Clementi AH, Mooney RA: Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417-3427, 2005
33. Weigert C, Hennige AM, Lehmann R, Brodbeck K, Baumgartner F, Schauble M, Haring HU, Schleicher ED: Direct cross-talk of interleukin-6 and insulin signal transduction via insulin receptor substrate-1 in skeletal muscle cells. J Biol Chem 281:7060-7067, 2006
34. Kelly M, Keller C, Avilucea PR, Keller P, Luo Z, Xiang X, Giralt M, Hidalgo J, Saha AK, Pedersen BK, Ruderman NB: AMPK activity is diminished in tissues of IL-6 knockout mice: the effect of exercise. Biochem Biophys Res Comm 320:449-454, 2004
35. Williamson DL, Bolster DR, Kimball SR, Jefferson LS: Time course changes in signaling pathways and protein synthesis in C2C12 myotubes following AMPK activation by AICAR. Am J Physiol Endocrinol Metab 291:E80-E89, 2006
36. Chan AYM, Soltys CLM, Young ME, Proud CG, Dyck JRB: Activation of AMP-activated protein kinase inhibits protein synthesis associated with hypertrophy in the cardiac myocyte. J Biol Chem 279:32771-32779, 2004
37. Krause U, Bertrand L, Hue L: Control of p70 ribosomal protein S6 kinase and acetyl-CoA carboxylase by AMP-activated protein kinase and protein phosphatases in isolated hepatocytes. Eur J Biochem 269:3751-3759, 2002
38. Faldt J, Wernstedt I, Fitzgerald SM, Wallenius K, Bergstrom G, Jansson JO: Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology 145:2680-2686, 2004
39. Lin TW, Cardenas L, Glaser DL, Soslowsky LJ: Tendon healing in interleukin-4 and interleukin-6 knockout mice. J Biomech 39:61-69, 2006
40. Baeza-Raja B, Munoz-Canoves P: p38 MAPK-induced nuclear factor-kappa B activity is required for skeletal muscle differentiation: role of interleukin-6. Mol Biol Cell 15:2013-2026, 2004
41. Fischer CP, Berntsen A, Perstrup LB, Eskildsen P, Pedersen BK: Plasma levels of interleukin-6 and C-reactive protein are associated with physical inactivity independent of obesity. Scand J Med Sci Sports. In press
42. Keller C, Steensberg A, Hansen AK, Fischer CP, Plomgaard P, Pedersen BK: The effect of exercise, training, and glycogen availability on IL-6 receptor expression in human skeletal muscle. J Appl Physiol 99:2075-2079, 2005
43. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH: Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52:812-817, 2003
44. Conn CA, McClellan JL, Maassab HF, Smitka CW, Majde JA, Kluger MJ: Cytokines and the acute phase response to influenza virus in mice. Am J Physiol Regul Integr Comp Physiol 268:R78-R84, 1995
45. Hill GE, Whitten CW: Proinflammatory mediator release after total hip arthroplasty. Anesthesiology 88:1407-1408, 1998
46. Singh R, Robinson DB, El-Gabalawy HS: Emerging biologic therapies in rheumatoid arthritis: cell targets and cytokines. Curr Opin Rheumatol 17:274-279, 2005
47. Helge JW, Stallknecht B, Pedersen BK, Galbo H, Kiens B, Richter EA: The effect of graded exercise on IL-6 release and glucose uptake in human skeletal muscle. J Physiol 546:299-305, 2003
48. Oberbach A, Tonjes A, Kloting N, Fasshauer M, Kratzsch J, Busse MW, Paschke R, Stumvoll M, Bluher M: Effect of a 4 week physical training program on plasma concentrations of inflammatory markers in patients with abnormal glucose tolerance. Eur J Endocrinol 154:577-585, 2006
49. Keller P, Keller C, Carey AL, Jauffred S, Fischer CP, Steensberg A, Pedersen BK: Interleukin-6 production by contracting human skeletal muscle: autocrine regulation by IL-6. Biochem Biophys Res Commun 310:550-554, 2003
50. Steensberg A, Keller C, Starkie RL, Osada T, Febbraio MA, Pedersen BK: IL-6 and TNF-alpha expression in, and release from, contracting human skeletal muscle. Am J Physiol Endocrinol Metab 283:E1272-E1278, 2002
51. Yang X, Jansson P-A, Pellme F, Laakso M, Smith U: Effect of the interleukin-6 (-174) G/C promoter polymorphism on adiponectin and insulin sensitivity. Obesity Res 13:813-817, 2005